Ref. | # | Median follow up (mo) | Stage | RT | Presciption dose | Local control | Dose to the optic pathway | Vision impairment | Blindness |
---|---|---|---|---|---|---|---|---|---|
Homma [10]§ | 47 | 55.2 | T4: 85.1% | 3D | 65 Gy/26 frx or 70 Gy/35 frx | 83.0% | n/a | 42.1% grade 3 or 4 optic toxicity at 2 years (CTCAE v.3); severe optic toxicity is 56% in patients with orbital invasion | None reported |
Gabriele [11]§ | 31 | 42 | T4: 38.7% | 3D | 60-68 Gy/30–34 frx | 61.3% | ON: | None | 2 due to disease progression, 1 due to cataract |
5 yr LC: | -Ipsilateral: 5.7-46.1 Gy | ||||||||
-Postoperative: 74% | -Contralateral: 3.8-25.6 Gy | ||||||||
-Definitive: 20% | OC: 11.3-36.2 Gy | ||||||||
Pommier [12]§ | 40 | 19 | T3-4: 55% | 3D | Definitive: 63.5 Gy¶ | 80% | ON: | None | 1 patient 3 years after RT due to vascular glaucoma |
Postoperative: 61.8 - 63.1 Gy¶ | -Ipsilateral 48.1 Gy¶ | ||||||||
2 Gy/frx | -Contralateral 22.0 Gy¶ | ||||||||
OC: 43.5 Gy¶ | |||||||||
Roa [13] | 39 | 54 | IV: 53.8% | 3D | Definitive: 68.4 Gyǂ; | 56.4% | n/a | 1 retinal artery occlusion and 1 optic neuropathy after 68.4 Gy delivered. | None |
Postoperative: 55.8 -67.8 Gyǂ | |||||||||
 |  |  |  |  | 1.8-2 Gy/frx |  |  |  |  |